Jennifer Sinquefield, APRN
Payments from drug & device makers
Across 82 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$471
- Novo Nordisk$143
- Astellas Pharma US Inc$121
- Seagen Inc.$118
- Incyte Corporation$103
- Amgen$79
- plus $820 from 26 others
What the payments were for
- Speaking & faculty fees$25013%
- Food & beverage$1,53583%
- Education$714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $471 |
| Novo Nordisk | 10 | $143 |
| Astellas Pharma US Inc | 4 | $121 |
| Seagen Inc. | 6 | $118 |
| Incyte Corporation | 6 | $103 |
| Amgen | 4 | $79 |
| Pfizer | 3 | $77 |
| AbbVie | 4 | $73 |
| Lilly USA, LLC | 4 | $64 |
| Johnson & Johnson | 3 | $54 |
| Octapharma USA, Inc. | 1 | $50 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| CSL Behring | 2 | $42 |
| Exact Sciences | 2 | $38 |
| Gilead | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $36 |
| GSK | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Dova Pharmaceuticals | 1 | $19 |
| Novartis | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Blue Earth Diagnostics | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $13 |
| Bayer | 1 | $13 |
| Bristol Myers Squibb | 1 | $12 |
How this compares
$1,856 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $102,609 |
| EliquisApixaban | 42 | $66,778 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $59,116 |
| TrulicityDulaglutide | 15 | $33,207 |
| MounjaroTirzepatide | 26 | $31,207 |
| FarxigaDapagliflozin Propanediol | 24 | $29,721 |
| JardianceEmpagliflozin | 17 | $26,237 |
| JanuviaSitagliptin Phosphate | 19 | $22,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,612 |
| XareltoRivaroxaban | 17 | $17,874 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,906 |
| MyrbetriqMirabegron | 12 | $10,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,841 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,133 |
| Levothyroxine Sodium | 538 | $5,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $143 | $102,60974 claims |
| Boehringer IngelheimStiolto Respimat, Jardiance | $16 | $85,35396 claims |
| PfizerEliquis | $77 | $66,77842 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $64 | $64,41441 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $471 | $53,76073 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $22 | $29,45337 claims |
| Johnson & JohnsonXarelto | $54 | $17,87417 claims |
| Astellas Pharma US IncMyrbetriq | $121 | $10,86512 claims |
| AbbVieSynthroid | $73 | $2,73561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Ocala
- Kelly BowmanOcala$316K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.